hexamethylene bisacetamide has been researched along with losartan potassium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hotta, T; Kagami, Y; Kinoshita, T; Mori, KJ; Murate, T; Ohashi, H; Saito, H; Tsushita, K; Yamashita, K; Yoshida, S | 1 |
| Asano, S; Miyajima, A; Wakao, H; Yamashita, T | 1 |
2 other study(ies) available for hexamethylene bisacetamide and losartan potassium
| Article | Year |
|---|---|
Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity.
Topics: Acetamides; Animals; Antibodies; Cell Differentiation; Cell Division; DNA, Neoplasm; Erythroid Precursor Cells; Erythropoietin; Friend murine leukemia virus; Gene Expression; Globins; Glycoproteins; Humans; Leukemia, Erythroblastic, Acute; Mice; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1993 |
Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line.
Topics: Acetamides; Animals; Antineoplastic Agents; Cattle; Cell Differentiation; Cytokines; DNA-Binding Proteins; DNA, Neoplasm; Erythropoietin; Fetal Blood; Friend murine leukemia virus; Janus Kinase 2; Leukemia, Erythroblastic, Acute; Mice; Milk Proteins; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Tumor Cells, Cultured | 1998 |